phospholipase A2 inhibitors (La Jolla)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namephospholipase A2 inhibitors (La Jolla)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhospholipases A2 inhibitors
TargetsPhospholipases A2
Therapy Area/IndicationsAsthmaInflammatory Bowel DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLa Jolla Pharmaceutical Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLa Jolla Pharmaceutical Company
Active IndicationsN/A
Inactive IndicationsAsthmaInflammatory Bowel DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A